ESRRA and breast cancer: Consistently, De Luca et al. [70] demonstrated that XCT790 – a selective inverse agonist ligand of the estrogen-related receptor alpha (ERRα), markedly reduced the oxidative phosphorylation in breast cancer cells and suppressed the activity of several signaling pathways that are normally required for the survival of CSCs, leading to inhibition of breast cancer stem cell propagation as determined with mammosphere formation assay.